

Contents

Preface.	vii
<i>Vassil St. Georgiev</i>	
Acknowledgments.	ix
Contributors	xv
PART I INTRODUCTION	
National Institute of Allergy and Infectious Diseases (NIAID): <i>An Overview</i>	3
<i>Karl A. Western</i>	
PART II MICROBIOLOGY AND INFECTIOUS DISEASES	
Section 1 Emerging and Re-Emerging Infections	
1 Biotools for Determining the Genetics of Susceptibility to Infectious Diseases and Expediting Research Translation into Effective Countermeasures	13
<i>Malak Kotb, Robert W. Williams, Nourtan Fathey, Mohamed Nooh, Sarah Rowe, Rita Kansal, and Ramy Aziz</i>	
2 Spore Surface Components and Protective Immunity to <i>Bacillus anthracis</i>	19
<i>Patricia Sylvestre, Ian Justin Glomski, Evelyne Couture-Tosi, Pierre Louis Goossens, and Michèle Mock</i>	
3 New Candidate Anthrax Pathogenic Factors	25
<i>Serguei G. Popov</i>	
4 <i>Ehrlichiae</i> and Ehrlichioses: <i>Pathogenesis and Vector Biology</i>	37
<i>H. L. Stevenson, N. Ismail, and D. H. Walker</i>	
5 Multiple Locus Variable Number Tandem Repeat (VNTR) Analysis (MLVA) of <i>Brucella</i> spp. Identifies Species-Specific Markers and Insights into Phylogenetic Relationships	47
<i>Lynn Y. Huynh, Matthew N. Van Ert, Ted Hadfield, William S. Probert, Bryan H. Bellaire, Michael Dobson, Robert J. Burgess, Robbin S. Weyant, Tanja Popovic, Shaylan Zanecki, David M. Wagner, and Paul Keim</i>	
6 Expression of the MtrC-MtrD-MtrE Efflux Pump in <i>Neisseria gonorrhoeae</i> and Bacterial Survival in the Presence of Antimicrobials.	55
<i>William M. Shafer, Jason P. Folster, Douglas E. M. Warner, Paul J. T. Johnson, Jacqueline T. Balthazar, Nazia Kamal, and Ann E. Jerse</i>	

Section 2 Tuberculosis

7	What can Mycobacteriophages Tell Us About <i>Mycobacterium tuberculosis</i> ?	67
	<i>Graham F. Hatfull</i>	
8	Clinical <i>Mycobacterium tuberculosis</i> Strains Differ in their Intracellular Growth in Human Macrophages.	77
	<i>Sue A. Theus, M. Donald Cave, and Kathleen D. Eisenach</i>	
9	Mechanisms of Latent Tuberculosis: <i>Dormancy and Resuscitation of Mycobacterium tuberculosis</i>	83
	<i>Galina Mukamolova, Elena Salina, and Arseny Kaprelyants</i>	
10	Separating Latent and Acute Disease in the Diagnosis of Tuberculosis	91
	<i>T. Mark Doherty</i>	
11	Mutant Selection Window Hypothesis: <i>A Framework for Anti-mutant Dosing of Antimicrobial Agents</i>	101
	<i>Karl Drlica and Xilin Zhao</i>	

Section 3 Avian Influenza

12	The NIAID Influenza Genome Sequencing Project	109
	<i>Lone Simonsen, Gayle Bernabe, Karen Lacourciere, Robert J. Taylor, and Maria Y. Giovanni</i>	
13	Lessons from the 1918 Spanish Flu Epidemic in Iceland.	115
	<i>Magnús Gottfredsson</i>	
14	Control of Notifiable Avian Influenza Infections in Poultry	123
	<i>Ilaria Capua and Stefano Marangon</i>	
15	Understanding the Complex Pathobiology of High Pathogenicity Avian Influenza Viruses in Birds	131
	<i>David E. Swayne</i>	

Section 4 Prophylactics and Therapeutics for Infectious Diseases

16	Development of Prophylactics and Therapeutics Against the Smallpox and Monkeypox Biothreat Agents.	145
	<i>Mark Buller, Lauren Handley, and Scott Parker</i>	
17	The Hierarchic Informational Technology for QSAR Investigations: <i>Molecular Design of Antiviral Compounds</i>	163
	<i>V. E. Kuz'min, A. G. Artemenko, E. N. Muratov, L. N. Ognichenko, A. I. Hromov, A. V. Liahovskij, and P. G. Polischuk</i>	
18	Antivirals for Influenza: <i>Novel Agents and Approaches</i>	179
	<i>William A Fischer, II and Frederick Hayden</i>	
19	Anti-Infectious Actions of the Proteolysis Inhibitor ϵ -Aminocaproic Acid (ϵ -ACA)	193
	<i>V. P. Lozitsky</i>	
20	A New Highly Potent Antienteroviral Compound	199
	<i>Lubomira Nikolaeva-Glomb, Stefan Philipov, and Angel S. Galabov</i>	

Section 5 Russian Perspectives in Emerging and Re-Emerging and Infections Research

21	Reduction and Possible Mechanisms of Evolution of the Bacterial Genomes.	205
	<i>George B. Smirnov</i>	
22	Interaction of <i>Yersinia pestis</i> Virulence Factors with IL-1R/TLR Recognition System.	215
	<i>Vyacheslav M. Abramov, Valentin S. Khlebnikov, Anatoly M. Vasiliev, Igor V. Kosarev, Raisa N. Vasilenko, Nataly L. Kulikova, Vladimir L. Motin, George B. Smirnov, Valentin I. Evstigneev, Nicolay N. Karkischenko, Vladimir N. Uversky, and Robert R. Brubaker</i>	

Contents	xiii
23 IS481-Induced Variability of <i>Bordetella pertussis</i>	227
<i>Ludmila N. Sinyashina, Alisa Yu. Medkova, Evgeniy G. Semin, Alexander V. Chestkov, Yuriy D. Tsygankov, and Gennagiy I. Karataev</i>	
24 Microarray Immunophosphorescence Technology for the Detection of Infectious Pathogens	233
<i>Nikolay S. Osin and Vera G. Pomelova</i>	
25 Development of Immunodiagnostic Kits and Vaccines for Bacterial Infections	241
<i>Valentina A. Feodorova and Onega V. Ulianova</i>	
Section 6 Perspectives in Emerging and Re-Emerging Infections—Research in Central Asia and Caucasus	
26 Research in Emerging and Re-Emerging Diseases in Central Asia and the Caucasus: Contributions by the the National Institute of Allergy and Infectious Diseases and the National Institutes of Health	251
<i>Katherine T. Herz</i>	
27 Disease Surveillance in Georgia: <i>Benefits of International Cooperation</i>	253
<i>Lela Bakanidze, Paata Imnadze, Shota Tsanava, and Nikoloz Tsertsvadze</i>	
28 Epidemiology (Including Molecular Epidemiology) of HIV, Hepatitis B and C in Georgia: Experience From U.S.–Georgian Collaboration	257
<i>Tengiz Tsertsvadze</i>	
29 The National Tuberculosis Program in the Country of Georgia: <i>An Overview</i>	263
<i>Archil Salakaia, Veriko Mirtskhulava, Shalva Gamtsemlidze, Marina Janjgava, Rusudan Aspindzelashvili, and Ucha Nanava</i>	
PART III HUMAN IMMUNODEFICIENCY VIRUS AND AIDS	
30 Virus Receptor Wars: <i>Entry Molecules Used for and Against Viruses Associated with AIDS</i>	271
<i>Edward A. Berger</i>	
31 HIV Latency and Reactivation: <i>The Early Years</i>	279
<i>Guido Poli</i>	
32 HIV-1 Sequence Diversity as a Window Into HIV-1 Biology	289
<i>Milloni Patel, Gretja Schnell, and Ronald Swanstrom</i>	
33 Human Monoclonal Antibodies Against HIV and Emerging Viruses	299
<i>Dimitar S. Dimitrov</i>	
34 Biological Basis and Clinical Significance of HIV Resistance to Antiviral Drugs	309
<i>Mark A. Wainberg and Susan Schader</i>	
35 NIAID HIV/AIDS Prevention Research	319
<i>David N. Burns and Roberta Black</i>	
36 Epidemiological Surveillance of HIV and AIDS in Lithuania	327
<i>Saulius Caplinskas</i>	
PART IV IMMUNOLOGY AND VACCINES	
Section 1 Immunomodulation	
37 TACI, Isotype Switching, CVID, and IgAD	343
<i>Emanuela Castigli and Raif S. Geha</i>	
38 A Tapestry of Immunotherapeutic Fusion Proteins: <i>From Signal Conversion to Auto-stimulation</i>	349
<i>Mark L. Tykocinski, Jui-Han Huang, Matthew C. Weber, and Michal Dranitzki-Elhalel</i>	

39	A Role for Complement System in Mobilization and Homing of Hematopoietic Stem/Progenitor Cells	357
	<i>M. Z. Ratajczak, R. Reca, M. Wysoczynski, M. Kucia, and J. Ratajczak</i>	
40	Post-translational Processing of Human Interferon- γ Produced in <i>Escherichia coli</i> and Approaches for Its Prevention	365
	<i>Maya Boyanova, Roumyana Mironova, Toshimitsu Niwa, and Ivan G. Ivanov</i>	
Section 2 Autoimmunity		
41	B-cell dysfunctions in Autoimmune Diseases	377
	<i>Moncef Zouali</i>	
42	A Model System for Studying Mechanisms of B-cell Transformation in Systemic Autoimmunity	385
	<i>Wendy F. Davidson, Partha Mukhopadhyay, Mark S. Williams, Zohreh Naghashfar, Jeff X. Zhou, and Herbert C. Morse, III</i>	
43	Breach and Restoration of B-Cell Tolerance in Human Systemic Lupus Erythematosus (SLE)	397
	<i>Iñaki Sanz, R. John Looney, and J. H. Anolik</i>	
Section 3 Infection and Immunity		
44	Dendritic Cells: <i>Biological and Pathological Aspects</i>	409
	<i>Jacques Banchereau, John Connolly, Tiziana Di Pucchio, Carson Harrod, Eynav Klechevsky, A. Karolina Palucka, Virginia Pascual, and Hideki Ueno</i>	
45	Immunomic and Bioinformatics Analysis of Host Immunity in the Vaccinia Virus and Influenza A Systems	429
	<i>Magdalini Moutafisi, Bjoern Peters, Valerie Pasquetto, Carla Oseroff, John Sidney, Huynh Hoa-Bui, Howard Grey, and Alessandro Sette</i>	
46	Immunoreactions to Hantaviruses	435
	<i>Alemka Markotić and Connie Schmaljohn</i>	
47	Innate Immunity to Mouse Cytomegalovirus	445
	<i>Djurdjica Cekinović, Irena Slavuljica, Tihana Lenac, Astrid Krmpotić, Bojan Polić, and Stipan Jonjić</i>	
Section 4 Vaccines		
48	Research and Development of Chimeric Flavivirus Vaccines	459
	<i>Simon Delagrave and Farshad Guirakhoo</i>	
49	Correlates of Immunity Elicited by Live <i>Yersinia pestis</i> Vaccine	473
	<i>Vivian L. Braciale, Michael Nash, Namita Sinha, Irina V. Zudina, and Vladimir L. Motin</i>	
PART V BUILDING A SUSTAINABLE PERSONAL RESEARCH PORTFOLIO		
50	Strategies for a Competitive Research Career	483
	<i>Hortencia Hornbeak and Peter R. Jackson</i>	
51	Selecting the Appropriate Funding Mechanism	487
	<i>Priti Mehrotra, Hortencia Hornbeak, Peter R. Jackson, and Eugene Baizman</i>	
52	Preparing and Submitting a Competitive Grant Application	497
	<i>Peter R. Jackson and Hortencia Hornbeak</i>	
53	Identifying Research Resources and Funding Opportunities	507
	<i>Eugene Baizman, Hortencia Hornbeak, Peter R. Jackson, and Priti Mehrotra</i>	
	Index	519